BACKGROUND: Hepatic artery lymph node (HALN) metastasis in pancreatic adenocarcinoma reportedly confers a survival disadvantage. This has led some authors to propose it as an indicator against pancreaticoduodenectomy (PD). METHODS: Consecutive patients who underwent PD during 2002-2012 were identified from the University of Louisville prospective hepatopancreaticobiliary database. Overall survival (OS) and disease-free survival (DFS) were estimated using Kaplan-Meier analysis. The log-rank test and multivariate Cox proportional hazards regression were used in further analyses. RESULTS: A total of 420 patients underwent PD during the period of study, of whom 197 had lymph node (LN) metastasis. Among these, 41 (20.8%) patients had disease-positive HALNs. The HALN was the only site of LN metastasis in only three of the 247 patients (1.2%). Median follow-up was 18.5 months (interquartile range: 4.1-28.2 months). Median OS and DFS were 22.7 months [95% confidence interval (CI) 19.0-26.3] and 12.6 months (95% CI 10.2-15.2). There was no significant difference in median OS between HALN-positive patients (18.4 months, 95% CI 12.3-24.0) and HALN-negative patients (19.7 months, 95% CI 16.7-22.6) (P = 0.659). On multivariate analysis, the hazard ratio (HR) of death was highest among patients with an LN ratio of >0.2 (HR 1.2, 95% CI 1.1-1.29; P = 0.012) followed by those with poorly differentiated histology (HR 1.09, 95% CI 1.04-1.11; P = 0.029). CONCLUSIONS: In pancreatic adenocarcinoma patients with LN disease, survival after PD is comparable regardless of HALN status. Therefore, HALN-positive disease should not preclude the performance of PD.
BACKGROUND:Hepatic artery lymph node (HALN) metastasis in pancreatic adenocarcinoma reportedly confers a survival disadvantage. This has led some authors to propose it as an indicator against pancreaticoduodenectomy (PD). METHODS: Consecutive patients who underwent PD during 2002-2012 were identified from the University of Louisville prospective hepatopancreaticobiliary database. Overall survival (OS) and disease-free survival (DFS) were estimated using Kaplan-Meier analysis. The log-rank test and multivariate Cox proportional hazards regression were used in further analyses. RESULTS: A total of 420 patients underwent PD during the period of study, of whom 197 had lymph node (LN) metastasis. Among these, 41 (20.8%) patients had disease-positive HALNs. The HALN was the only site of LN metastasis in only three of the 247 patients (1.2%). Median follow-up was 18.5 months (interquartile range: 4.1-28.2 months). Median OS and DFS were 22.7 months [95% confidence interval (CI) 19.0-26.3] and 12.6 months (95% CI 10.2-15.2). There was no significant difference in median OS between HALN-positive patients (18.4 months, 95% CI 12.3-24.0) and HALN-negative patients (19.7 months, 95% CI 16.7-22.6) (P = 0.659). On multivariate analysis, the hazard ratio (HR) of death was highest among patients with an LN ratio of >0.2 (HR 1.2, 95% CI 1.1-1.29; P = 0.012) followed by those with poorly differentiated histology (HR 1.09, 95% CI 1.04-1.11; P = 0.029). CONCLUSIONS: In pancreatic adenocarcinomapatients with LN disease, survival after PD is comparable regardless of HALN status. Therefore, HALN-positive disease should not preclude the performance of PD.
Authors: M Kayahara; T Nagakawa; H Kobayashi; K Mori; T Nakano; N Kadoya; T Ohta; K Ueno; I Miyazaki Journal: Cancer Date: 1992-10-15 Impact factor: 6.860
Authors: Timothy M Pawlik; Eddie K Abdalla; Carlton C Barnett; Syed A Ahmad; Karen R Cleary; Jean-Nicolas Vauthey; Jeffrey E Lee; Douglas B Evans; Peter W T Pisters Journal: Arch Surg Date: 2005-06
Authors: T M Breslin; K R Hess; D B Harbison; M E Jean; K R Cleary; A P Dackiw; R A Wolff; J L Abbruzzese; N A Janjan; C H Crane; J N Vauthey; J E Lee; P W Pisters; D B Evans Journal: Ann Surg Oncol Date: 2001-03 Impact factor: 5.344
Authors: O Ishikawa; H Ohigashi; Y Sasaki; T Kabuto; H Furukawa; S Nakamori; S Imaoka; T Iwanaga; T Kasugai Journal: Surgery Date: 1997-03 Impact factor: 3.982
Authors: Shishir K Maithel; Korosh Khalili; Elijah Dixon; Maha Guindi; Mark P Callery; Mark S Cattral; Bryce R Taylor; Steven Gallinger; Paul D Greig; David R Grant; Charles M Vollmer Journal: Ann Surg Oncol Date: 2007-01 Impact factor: 5.344
Authors: S Connor; L Bosonnet; P Ghaneh; N Alexakis; M Hartley; F Campbell; R Sutton; J P Neoptolemos Journal: Br J Surg Date: 2004-12 Impact factor: 6.939
Authors: J LaFemina; J F Chou; M Gönen; F G Rocha; C Correa-Gallego; T P Kingham; Y Fong; M I D'Angelica; W R Jarnagin; R P DeMatteo; P J Allen Journal: J Gastrointest Surg Date: 2013-04-16 Impact factor: 3.452
Authors: Timothy M Pawlik; Ana L Gleisner; John L Cameron; Jordan M Winter; Lia Assumpcao; Keith D Lillemoe; Christopher Wolfgang; Ralph H Hruban; Richard D Schulick; Charles J Yeo; Michael A Choti Journal: Surgery Date: 2007-03-23 Impact factor: 3.982
Authors: Lennart B van Rijssen; Poorvi Narwade; Nadine C M van Huijgevoort; Dorine S J Tseng; Hjalmar C van Santvoort; Isaac Q Molenaar; Hanneke W M van Laarhoven; Casper H J van Eijck; Olivier R C Busch; Marc G H Besselink Journal: HPB (Oxford) Date: 2016-05-27 Impact factor: 3.647
Authors: Aaron J Grossberg; Linda C Chu; Christopher R Deig; Eliot K Fishman; William L Hwang; Anirban Maitra; Daniel L Marks; Arnav Mehta; Nima Nabavizadeh; Diane M Simeone; Colin D Weekes; Charles R Thomas Journal: CA Cancer J Clin Date: 2020-07-19 Impact factor: 508.702